A Dual-guide RNA Treatment for Hepatitis B

Excision BioTherapeutics’ EBT-107 program is intended to treat individuals with hepatitis B (HBV) by targeting HBV-infected cells in the liver.

Our Pipeline



HBV non-viral CRISPR/Cas dual gRNA Therapeutic

Discovery/Validation Preclinical Cleared IND Clinical Trials
Discovery/Validation Phase in progress
Preclinical Phase not started
Cleared IND Phase not started
Clinical Trials Phase not started

$50 Billion Market Opportunity

~1.2 million in the U.S.

~350 million patients worldwide1

1) CDC, https://www.cdc.gov/hepatitis/hbv/pdfs/hepbatrisk.pdf. 2021.

Other Pipeline Programs


Targeting HIV-infected cells in viral tissue reservoirs and systemic circulation.

Learn More


Targeting herpes virus-infected cells in peripheral nervous system (PNS) ganglia.

Learn More

The Innovative Technology That Drives Our Programs

Our cutting-edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.

More About Our Technology

Research & Publications

View our library of publications for more information on the research behind our CRISPR gene-editing technology.

View Publications